Upload
delphia-harper
View
220
Download
0
Tags:
Embed Size (px)
Citation preview
Research & Innovation
Horizon 2020
Research & Innovation
European perspectives in healthcare sciences and implementation
Horizon 2020 Information Day12 September 2013
Brussels
From omics to health promotion – novel approaches and collaborations
Research & Innovation
Disclaimer
Pending formal adoption by the EU of the Horizon 2020 legal texts, the content of these slides is not definitive and so should not be taken as such, nor used or referred to as such in any way or for any purpose
!
Research & Innovation
Workshop agenda14:00-14:45 Using omics data and personalised medicine in healthcare
• Health promotion and diseases prevention, translating omics into stratified approaches
• Piloting personalised medicine in health and care systems
• Questions and Answers
14:45-15:30 Reaching out to other sectors
• Health promotion and disease prevention: improved inter-sector co-operation for environment and health based interventions
• Foresight for health policy development and regulation
• Questions and Answers
15:30 – 16:00 Coffee break
16:00-17:00 Looking for efficiency gains
• Evaluating existing screening and prevention programmes
• Developing and comparing new models for safe and efficient, prevention oriented, health and care systems
• Questions and Answers
Research & Innovation
"From 'omics' to health promotion - novel approaches and collaborations"
Research & Innovation
WORK PROGRAMME
"Impacts, challenges and
limitations of EU-funded public
health research - Priorities for
future research" Report of an
independent Expert Group
Consultation workshop on
future of public health
research, January 31, 2013
Health 2020: the European
policy for health and well-being
"Use of '-omics' technologies in
the development of personalised
medicine" – Staff working
document
BACKGROUND
NOVEL APPROACHES COLLABORATIONS
COMMISSION SERVICES MEMBER STATES
Research & Innovation
EnvironmentalDeterminants
CLIMATE CHANGE
&DISASTERS:
• Heatwaves• Fires• Drought• Floods• Mudslides• Chemical Spills
• Food Security• Changes in • Infectious
disease habitat
Social & Economic
Determinants
AGEING
ECONOMIC DECLINE
INEQUALITIES
URBANISATION
MIGRATION
TECHNOLOGY
Health Outcomes
NCDs
LONGERLIFE
EXPECTANCY
Health SystemImplications
INCREASED:DEMAND & COSTS
DECREASEDWORKFORCE
Solutions
SUSTAINABLEPREVENTION& PROMOTION
PRIMARYHEALTH
CARE & Health systems
tranformation
PROTECTIONEmergency
preparedness
INNOVATIVEWIN – WIN-WIN
APPROACHESE.g. Personalised
medicine
Risks & Projections (Foresight) RESEARCH IMPLICATIONS Innovative solutions
Public Health Challenges and possible solutions for 2050*
*Courtesy: Division of Health Systems and Public Health, WHO Regional Office for Europe
Novel approaches collaborations
Research & Innovation
Novel approaches & collaborations
• Learning from the past:
• Clear EU added value
− Research that clearly demonstrate a potential for translation and policy uptake to benefit the health of all EU citizens
− Research that would not necessarily be supported by national funding agencies.
• Importance of knowledge translation & capacity building for effective uptake
Research & Innovation
Novel approaches and collaborations
• Looking towards the future
• More action oriented research
• Multi stakeholder, multi-disciplinary research
• Change of mind set
Research & Innovation
Using omics data and personalised medicine in healthcare
Research & Innovation
Personalised medicine – towards a definition
"Personalised medicine refers to a medical model using molecular profiling for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention"
Research & Innovation
• Non-communicable diseases worldwide will cause an output loss of €35 trillion over the next two decades
• Current medical treatments
• Increasing pressure on European healthcare systems
• The EU is not closing the persistent gap with global innovation leaders
• Biomedical companies are finding drug development in Europe economically challenging
Personalised medicine to address significant challenges…
Research & Innovation
…and benefit from opportunities
• Stratified and subsequently personalised medicine can deliver better outcomes for patients and potential cost savings
• Recent studies suggest cost savings of 37% for breast cancer and 46% for CVD when a stratified approach is taken
• Europe can lead implementation of personalised medicine thanks to favourable conditions
Research & Innovation
Healthcare opportunities: making medical treatments more personalised
• Avalanche of new –omics and molecular information following the sequencing of the human genome
• Translation of – omics from basic to clinical research can bring us better understanding of health and disease
• Need innovative approaches for changing the focus from
treatment and cure to prediction and prevention
Clinical definition of disease
Molecular definition of disease
Molecular definition of health
Research & Innovation
Personalised Medicine Workshops & conference
• Vision for Europe 2020: identify bottlenecks for PM implementation into clinical practise
• 2010: Preparatory workshops (-omics, biomarkers, clinical trials/regulatory, uptake)
• 2011: European Perspectives in PM conference
Available on: http://ec.europa.eu/research/health
Research & Innovation
“Omics”
Technologies
Data
Samples
Statistics
R&Dthe basics
R&D stratifying
tools
R&Dtest in human
In patients
Uptake in healthcare
Towards the market
Clinical trials MethodologiesEthics
Patient -recruitment
Diagnostics & Therapies
Approval processes
Regulatory aspects
Pricing &Reimbursement
Health economy
HTA
Novel models of healthcare organisation
Prediction - Prevention – Treatment - Cure
Availability & usability in the clinic
Patient perspective
Equal treatment
Training of professionals
Personalised Medicine: a novel approach with many challenges along the way
BiomarkersIdentificationQualificationValidation
Data modelling tools
Technical aspects & challenges
Research & Innovation
EU Health Research Programme: Enabling personalised medicine 2007-2013
• large scale data gathering and "-omics"
• technology development
• diagnostics
• biomarkers
• pre-clinical and clinical research
• public health research
• IMI projects with pharma industry
Over 1 billion EUR to top research
Research & Innovation
Overview 2007-2013 Large-scale data gathering
Resources
Genomics & other -omics
Genetic epidemiology
International cooperation
Model organisms
Structural biologyand Cell biology
Basic knowledge
genetic/genomic epidemiology genetic epidemiology of disease
(hypertension, infections, pre-eclampsia...)
proteomicslipidomics
epigenomicscancer genomics
metagenomicsproteomics standardisation
receptors, channels & transporters, signalling proteins
Stem cells
zebrafish, fly, mouse (IKMC), rat & dog as models for human disease
35 projects€ 351 million
Research & Innovation
International K.O. Mouse Consortium
Contributing to international cooperation
International Human Microbiome Consortium
International Human Epigenome Consortium
International Rare Diseases Research
Consortium
International Initiative for Traumatic Brain
Injury Research
© rtg
uest/Fo
tolia
.com
Global Alliance for Chronic Diseases
Global Research Collaboration for Infectious
Disease Preparedness
Overview 2007-2013 Large-scale data gathering
International Cancer Genomics Consortium
Research & Innovation
• Structuring research areas within EU and beyond
• Setting standards of high quality data collection, integration and analysis
• Open access data repositories
Main achievements
Project example: BLUEPRINT
• BLUEPRINT preliminary results enable discovery of causative epigenetic factor for rare blood disease (TAR syndrome)
Overview 2007-2013 Large-scale data gathering
Research & Innovation
Staff Working Document onUse of '-omics' technologies in the development of personalised medicine
• the potential for, and issues with, the use of '-omics' technologies in personalised medicine, and the related EU research funding
• recent developments in EU legislation for placing medicinal products and devices on the market
• factors affecting the uptake of personalised medicine in health care systemsAvailable on: http://ec.europa.eu/health/files/latest_news/2013-10_personalised_medicine_en.pdf
Research & Innovation
Use of '-omics' technologies in the development of personalised medicine Main Conclusions
• Horizon 2020 to address research challenges
• Efficient regulatory framework for medicines and in vitro diagnostics
• EU cooperation in HTA
-> essential responses from the EU to the current challenges
-> continued fruitful dialogue with all stakeholders
Research & Innovation
Identified Key research challenges
Translating knowledge to medical applications
disease taxonomy, biomarker validation, clinical trials
Understanding the value & economic aspects health care pilots, HTA, comparative effectiveness research, value chain
Breaking barriers & speaking the same language
"cross-disciplinarity", capacity building, education & training
Generating knowledge & developing the right tools
standards, clinical bioinformatics, adaptation of tools
Research & Innovation
Health promotion and diseases prevention: translating omics into
stratified approaches
(2014 topic)
Research & Innovation
• ‘Omics’ research (including but not limited to genomics, epi-genomics, meta-genomics and proteomics) is moving at a breath-taking pace.
• A major challenge for the next decade is to determine when and how this wealth of ‘omics’ information can be usefully applied by both the public and private sectors for the development of personalised /stratified approaches in health promotion and disease prevention.
Translating omics into stratified approaches for health promotion and disease prevention: Specific Challenge
Research & Innovation
proteomics
epi-genomics
genomics
transcriptomicsmeta-genomics
…. - omics
"-omics"
economics
Research & Innovation
• Develop and assess a personalised / stratified health promotion or disease prevention programme, taking into account the ‘omics’ characteristics of individuals, complemented by environmental and/or lifestyle factors
• Include the development of tools and methods for the use of 'omics' data in such programmes
Translating omics into stratified approaches for health promotion and disease prevention: Scope
Research & Innovation
• Include a multi-disciplinary approach to assess the validity and utility of ‘omics’ data in preventive medicine or in prevention programmes targeting specific population groups. This should include:
• The assessment of the predictive value of such programmes in identifying at-risk groups throughout their lives, as compared with conventional methods;
• The assessment of the usefulness of ‘omics’ data for improving the health of individuals or populations;
• The assessment should take into account age and gender aspects where appropriate.
• The assessment of the behavioural, ethical, legal, regulatory and social implications, as well as of the cost-effectiveness of the programme
Translating omics into stratified approaches for health promotion and disease prevention: Scope continued
Research & Innovation
• Include risk-benefit communication to various groups involved in such a programme, including individuals, policy makers and regulators
• Preference will be given to proposals focusing on diseases with either high prevalence or which present a high risk to the individual, or a high cost to society
Translating omics into stratified approaches for health promotion and disease prevention: Scope continued
Research & Innovation
• Evidence on the validity, utility and cost-effectiveness of ‘omics’ based health promotion and disease prevention programmes, allowing informed decisions on the organisation of health and care systems
• Budget: proposed EU contribution of between € 4-6 M (total budget € 24 M)
Translating omics into stratified approaches for health promotion and disease prevention: Expected impact and budget
Research & Innovation
Examples of relevant on-going projects
Predicting Human Metabolic Responses Using Advanced Genomics
METAPREDICT aims to combat diabetes, obesity and cardiovascular disease through translational discoveries by producing molecular ‘predictors’ for the personalised clinical response to exercise training.
www.metapredict.eu
Research & Innovation
Examples of relevant on-going projects
Epigenetics for Personalised Care of Female Cancers
EPIFEMCARE aims to develop new methods for screening, diagnosing and personalising treatment of breast and ovarian cancers.
www.epifemcare.eu
Research & Innovation
Piloting personalised medicine in health and care systems
(2015 topic)
Research & Innovation
• Personalised medicine has the potential to respond to, amongst others, the increasing burden of chronic disease and the complexity of co-morbidities, and in doing so contribute to the sustainability of health and care systems.
• If this potential is to be realised at a larger scale it must first be demonstrated in terms of sustainable benefits, and as a new model of care organisation. Demonstration is however complicated by the diversity of European Union health systems.
Piloting PM in health and care systemsSpecific Challenge
Research & Innovation
Piloting PM in health and care systemsScope• Pilots of new models of care, based on the concept
of personalised medicine will be conducted in existing health care environments and should take into account Europe's (national and regional) diversity in health system organisation.
• Proposal should ensure coordination with national, regional or local authorities engaging in health sector reform with the design of new models taking into account the views of other relevant stakeholders, including policy makers and citizens. Behavioural, ethical, legal, social implications as well as the gender dimension should be addressed
Research & Innovation
• The health, economic and social impact of the implementation of these pilots on individual patients, whole or stratified population groups, and their impact at the level of health care systems should be assessed
• The organisational and resource requirements of the piloted models (data, personnel and financing) should be tracked, providing evidence on methods of implementation and benefits of reform while ensuring safety, equity and cost effectiveness. Appropriate measures for knowledge transfer and capacity building should be put in place
Piloting PM in health and care systemsScope continued
Research & Innovation
• On the basis of quantitative and qualitative indicators, evidence for a validated model of organisation of care based on the concept of personalised medicine should be produced, to be used by policy makers and decision makers in making improvements to health and care systems
• Budget: proposed EU contribution of between € 12-15 M (Total budget € 30 M)
Piloting PM in health and care systemsExpected impact and budget
Research & Innovation
Examples from the EuroBioForum's Personalised Medicine Observatory
www.eurobioforum.eu
Personalised medicine in Europe
Research & Innovation
Personalised medicine in Europe
www.medizin.uni-greifswald.de/GANI_MED
www.cancerresearchuk.org
www.imtm.cz
www.geenivaramu.ee
Research & Innovation
French National Cancer Institute (INCA)
www.e-cancer.frSource: F. Calvo presentation 13-05-2011
Economic impact of molecular testing
Cancer Drug Biomarker
% patients
with mutation
Nb of tested
patients
Number of spared
prescriptions
Median PFS for
non responder
s
Cost of treatment/
patientSpared cost
Public fundings allocated for
the provision of the test
lung cancer
gefitinib EGFR mut
10,3% 1672215000 8 weeks 4 600 €
€69 M €1.7 Merlotinib 15000 8 weeks 4 600 €
colorectal cancer
cetuximab KRAS
mut36% 17250 6 210
8 months
32 419 € € 201 M
€2.5 M8 weeks 9 263 € €57 MPanitu-mumab
4 weeks 4 390 € €27 M
Research & Innovation
Time for questions
Research & Innovation
Thank you
www.ec.europa.eu/research/health
www.ec.europa.eu/research/horizon2020
Research & Innovation
REACHING OUT TO OTHER SECTORS
Research & Innovation
The determinants of health
Research & Innovation
The determinants of health – an example
The Journal of The Royal Society for the Promotion of Health JRSH, November 2006 Vol 126 No 6
Research & Innovation
Reaching out to other sectors
• Health is not the responsibility of the health sector only
• Health is a result of a number of factors, individual and social
• There is solid evidence that health can be influenced by policies in other sectors, and that health has, in turn, important effects on the realization of the goals of other sectors, such as economic wealth.
• Need for action at many levels for disease prevention and health promotion
• Break down the silos
• Capitalise on various fields of expertise
Research & Innovation
Inter-sectoral Governance for Health in all policies
• Health in All Policies encourages an inter-sectoral approach which is necessary to tackle challenges such as climate change, NCDs, ageing etc….
• It goes beyond the boundaries of the health sector, to link with policies such as transport, housing, the environment, agriculture, education, fiscal policies, tax policies and economic policies.
Research & Innovation
Reaching out to other sectors – call topics –
• PHC 4 - Health promotion and disease prevention: improved inter-sector co-operation for environment and health based interventions
• PHC 31 - Foresight for health policy development and regulation
Research & Innovation
Reaching out to other sectors – call topics –
PHC 4
Health promotion and disease prevention: improved inter-sector
co-operation for environment and health based interventions
Research & Innovation
Personalised exposure
monitoring
Early intervention
s
Testing
EMISSION SOURCES
CLIMATE CHANGE
LIFE-STYLE
SOCIO-ECONOMICS
EXTERNAL EXPOSURE
INTERNAL EXPOSURE
HEALTH/ DISEASE
TREATMENT
DIAGNOSIS
Mechanisms
Cohorts
Omics
Surveys
Bio-markers
Epigenetic programming
Environment andHealth Research
Molecular epi-
demiology Mixture toxicity
Challenges
Tools for integrated environment and health impact assessment
Research & Innovation
The SCOPE of this topic is limited to the integration of environment, climate and health sectors (including but not limited to air quality, water and sanitation, chemicals, occupational factors, etc.).
APPROACH:
multidisciplinary involving relevant stakeholders such as policy makers,
the private sector, civil society organisations and so on
PHC 4 - Health promotion and disease prevention: improved inter-sector
co-operation for environment and health based interventions - in 2015
Research & Innovation
Proposals should address all of the following elements:
1. Develop inter-sector interventions (and/or policy initiatives) to promote health or prevent disease based on known environmental stressors.
• These inter-sector interventions will address key environmental stressors for which changes in relevant EU and international policies related to environment, climate and health would have the greatest impact.
• In the development of these interventions, age and gender aspects should be taken into account where appropriate.
PHC 4 - SCOPE (continued)
Research & Innovation
2. Document success characteristics of the abovementioned inter-sector interventions, including those factors that help to overcome barriers to inter-sector co-operation; contextual factors such as the interplay between politics and economics should be addressed;
3. Assess these inter-sector interventions for their health, economic and social benefits and their impact on reducing inequalities.
To note: Research activities will be developed as a European contribution to existing international activities and those under development
PHC 4 - SCOPE (continued)
Research & Innovation
PHC 4 - Expected impact and budget
Impact:
• On the basis of quantitative and qualitative indicators, evidence on effective interventions taking a ‘health in all’ approach, linking environment, climate and health, allowing informed decisions on multi-sector interventions and related policies.
• Impact on health and care systems and other public services in terms of their sustainability,
• Contribution to the EU commitment to the Rio+20 agenda and the new UN Sustainable Development Goals (SDGs), as well as to the Parma declaration 2010
Budget: proposed EU contribution of between € 4-6 M (total budget € 18 M)
Research & Innovation
Time for questions
Research & Innovation
Reaching out to other sectors – call topics –
PHC 31
Foresight for health policy development and regulation
Research & Innovation
Foresight to…
• Support more informed decisions for planning with a 5-20 years perspective – basis for policy dialogue
• Explore multiple futures and their consequences
• Assess risks – known risks/unknown risks
• Consider long-term changes in social, economic, technological and ecological environment
• help select best indicators to allow forecasting
Research & Innovation
Reaching out to other sectors- Foresight for health -
• Invest now in research to address the health challenges of the future - Foresight can facilitate the definition of strategic research and innovation goals for the short, mid- and long-term
• Challenges to health come from outside and within the sector
Research & Innovation
SCOPE
• to identify key driving forces- (external and internal to the health systems) likely to influence health and wellbeing in Europe and beyond in the future.
• to contribute to the understanding of the inter-relationships between these factors; analyse their economic and social impact and suggest alternative policy options to respond to the challenges they pose.
PHC 31 - Foresight for health policy development and regulation
Research & Innovation
PHC 31 - SCOPE (continued)
• to present a comprehensive, structured and participatory framework of analysis, integrating and quantifying key factors impacting health, health inequalities and demand for health services taking Europe's diversity into account. Use of Copernicus data, products and information may be considered where relevant.
• Use should be made of current techniques for foresight such as: horizon scanning, trend monitoring, and analysis based on epidemiological surveillance (of health and health determinants), weak signal analysis, expert opinion (to create collective intelligence), scenario development, back-casting and wildcards (to help define alternative futures).
Research & Innovation
Proposals should
• Include quantitative analysis, such as environment, health, economic and other modelling and sensitivity analysis to measure variation in impact of different factors.
• Include the identification and validation of relevant measures & indicators and the development of (common) standards.
• Capitalise on existing good practice in Europe as well as international level experiences.
PHC 31 - SCOPE (continued)
Research & Innovation
• The usefulness of current health data and statistics for these modelling exercises should be assessed and suggestions for improvement made.
• Proposals should also include networking between centres with existing expertise in (health) foresight, both public and private, and partnerships with centres aspiring to develop this expertise.
• If more than one proposal is successful, proposals should collaborate.
PHC 31 - SCOPE (continued)
Research & Innovation
PHC 31 - Expected impact & Budget
Impact:• Through the use of a validated analytical framework with a
robust set of standardised indicators, the ability to model and track the impact of various factors (internal and external to the health systems) on population health should be improved.
• A basis for policy dialogue, facilitating timely decision making in the EU MS and beyond with regards to health sector reform and guide investments in health care to improve population health.
• Guidance for future health research
Budget: proposed EU contribution of between € 2-3 M (total budget € 6M)
Research & Innovation
Time for questions
Research & Innovation
LOOKING FOR EFFICIENCY GAINS
Research & Innovation
Research & Innovation
Health systems under stress
• Health spending is growing at a faster pace than GDP
• Driven by: ageing population; increasing patients expectations and demands on health care…
• Health inequalities are rising
=> need for transformation to ensure cost effectiveness & sustainability and access to high quality healthcare
Research & Innovation
Wanted:
• Through better health promotion and disease prevention, fewer ‘chronic patients’
• Simpler, more personalised and cost-effective technologies and treatments
• Integrated and patient-centred services
• Safety, quality and continuum of care
• Diverse and skilled health workforce
Health System Transformation
Investing now in the right
research will pay off
Research & Innovation
Health System Transformation – starting point –
A report from the US Preventive Services Task
Force recommends against prostate cancer screening
In the past 12 months alone, the BMJ, the Lancet, and the
New England Journal of Medicine have published 24 articles or communications
debating the value of breast cancer screening
"We need a continued focus on the cost-effectiveness of population
based disease prevention interventions, including the
‘deprogramming’ of interventions that are known
to be ineffective" Eur J Public Health (2013) 23 (5): 722. doi:
10.1093/eurpub/ckt102
More efficient use of available resources
Disinvesting in ineffective or not cost effective
screening programmes
Research & Innovation
Evaluating screening & prevention programmes
• It is about reassessing a programme in light of new
evidence and practice
• Allows further programming or deprogramming
where relevant
=> More efficient use of resources
Research & Innovation
• Proposals should assess existing screening and disease prevention strategies and programmes, at the level of the individual or stratified population groups and across Europe, on the basis of:
health outcomes,
quality-of-life,
equity and cost-effectiveness
and ethical considerations,
• The gender dimension should be taken into account where relevant.
PHC 6 - Evaluating existing screening and prevention programmes
SCOPE
Research & Innovation
• Comparison between different countries and regions, demographic groups and cultures should be made in order to identify specific contextual links as well as to identify opportunities for exchange of knowledge and experience between countries and regions.
• Proposals should include the development of new methods or the adaptation of existing ones for this type of assessment. These methods and tools (including self-assessment tools) should be applied in different health systems and organisational infrastructures to test their applicability in different political, economic and societal contexts.
PHC 6 - SCOPE (continued)
Research & Innovation
• Due attention should be paid from the outset to the further development and dissemination of methodological expertise, including capacity building across Europe, in order that the expertise generated is fully exploited.
PHC 6 - SCOPE (continued)
Research & Innovation
PHC 6 - Expected impact & budget
Impact:• Evidence for the increased use, or discontinuation of,
existing screening and prevention programmes allowing informed decisions by policymakers
• Capacity building in the assessment of such screening and prevention programmes.
• Improved health outcomes, greater health equity and cost effectiveness based on the implementation of effective screening and prevention programmes
Budget: proposed EU contribution of between € 2-3 M (total budget € 15M)
Research & Innovation
Time for questions
Research & Innovation
Health System Transformation – starting point –
More efficient use of available resources
In search of new models, more prevention oriented
Research & Innovation
Health System Transformation – In search of new models…..
• "At the same time, Primary Health Care (PHC) reforms, and the PHC movement that promotes them, have to be more responsive to social change and rising expectations that come with development and modernization.(...) This requires delicate trade-offs and negotiation with multiple stakeholders that imply a stark departure from the linear, top-down models of the past". (The World Health Report 2008; Primary Health Care Now More Than Ever.)
• Press release of the American Medical Association - Nov. 18, 2013WASHINGTON -- Team-based health care delivery models are quickly emerging as the preferred method for providing coordinated, cost-effective, high-quality health care for patients and today the American Medical Association's House of Delegates adopted new recommendations for creating payment mechanisms to sustain these promising new models of care.
• In the long term, the sustainability of Europe’s healthcare systems will depend on two factors: reorienting its focus from treating illness to promoting health, and improving the management of chronic diseases to make it both more effective and more cost-efficient. (Economist Intelligence Unit (2012): Never too early: Tackling chronic disease to extend healthy life years)
• ”… the way to get costs lower is to move care farther and farther from the hospital setting — and even out of doctors’ offices." George C. Halverson – CEO Kaiser Permanente
Research & Innovation
SCOPE:
• As action oriented research, proposals should develop new, or improve on existing, models for health systems, in order to make these systems more patient-centred, prevention oriented, efficient, resilient to crises, safe and sustainable.
• The models’ applicability and adaptation to different European health systems and EU regions should be assessed, and their value, including individual and societal benefits, demonstrated.
PHC 23 - Developing and comparing new models for safe and efficient, prevention
oriented, health and care systems:
Research & Innovation
• Models may apply to different levels within the health system (micro – the patient interaction level, meso- the health care organization and community level, and macro - the policy level).
• They must be compared with alternatives (including existing models), capitalising on Europe's diversity.
• Views of relevant stakeholders such as policy makers and citizens should be taken into account in the design of and evaluation of these models.
• The gender dimension should be duly addressed.
• Capacity building and awareness raising activities for the adoption and further use of models developed should be included.
PHC 23 - SCOPE (continued)
Research & Innovation
• Proposals should address the related challenge of ensuring appropriate and sufficient resources (human, financial, infrastructural, equipment (or consumables) and technology) for these new models and develop adequate governance mechanisms.
• Proposals may include methodological work in the field of health technology assessment, health systems performance assessment, health workforce analysis as well as indicators and measures to describe and monitor the quality of life of European citizens adequately, taking into account the diverse socio-demographic groups and cultural backgrounds, and should track costs.
PHC 23 - SCOPE (continued)
Research & Innovation
PHC-23 - Expected impact and budget
Impact:
• On the basis of quantitative and qualitative indicators, evidence for new or improved patient-centred, prevention oriented, safe and efficient models for health care systems and services.
• Evidence to be used by policy makers and decision makers in making improvements to health and care systems, health and other policies
Budget: proposed EU contribution of between € 4-6 M (total budget € 30 M)
Research & Innovation
Time for questions
Research & Innovation
Thank you
www.ec.europa.eu/research/health
www.ec.europa.eu/research/horizon2020